Growth Hormone
Ipamorelin
Ipamorelin (selective GH secretagogue)
Selective ghrelin receptor agonist · stimulates GH without prolactin/cortisol increase
- FDA Status
- Not FDA-approved · Investigational · Compounding restricted
- Class
- Pentapeptide · GHRP class
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Half-life
- ~2 hours
Mechanism of action
- Selective ghrelin/GHS-R1a receptor agonism
- Pulsatile GH release mimicking physiological pattern
- No significant effect on prolactin, cortisol, or aldosterone (vs older GHRPs)
- Mild effect on appetite (less than GHRP-6)
Research areas
- Growth hormone deficiency in adults
- Sarcopenia and muscle wasting (preliminary)
- Post-operative recovery
- Investigational: bone density, fat redistribution
Evidence and clinical data
Phase II human trials demonstrated GH stimulation without the side-effect profile of older GHRPs (GHRP-2, GHRP-6). Generally considered the cleanest secretagogue. Limited Phase III data.
Safety profile
Best-tolerated of the GHRP class. Common AEs: head-flush, mild headache. No significant cortisol or prolactin shifts. Long-term IGF-1 trajectory needs more data.
Why this peptide is trending in 2026: Often paired with CJC-1295 in "GH protocols" within longevity and bodybuilding communities. Demand driven by anti-aging and recovery claims.
Educational use only. PeptideAdvance does not sell Ipamorelin, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.